Copyright © 2003 by the European Society of Cardiology.
Outcome after treatment of coronary in-stent restenosis
Results from a systematic review using meta-analysis techniques
a Royal Brompton & Harefield NHS Trust, London, UK
b Department of Cardiology, RWTH University Hospital Aachen, Aachen, Germany
c London School of Hygiene and Tropical Medicine, Medical Statistics Unit, London, UK
Received December 19, 2001; accepted February 27, 2002 * Corresponding author. Department of Cardiology, RWTH University Hospital, Pauwelsstrasse 30. D-52057 Aachen, Germany
u.sigwart{at}rbh.nthames.nhs.uk
Aims To evaluate the clinical outcome after treatment of coronary in-stent restenosis.
Methods and results For identification of the relevant literature a specific search strategy was conducted and explicit inclusion criteria were defined to avoid selection bias. Based on the selected literature, a systematic review using descriptive statistics and meta-analysis methods regarding the outcome after treatment of coronary in-stent restenosis was performed. The proportion of patients experiencing a major adverse cardiac event (MACE) as defined by death, myocardial infarction, and target lesion revascularization was the main outcome measure. A total of 1304 citations were identified. Among these, 28 studies (six different treatment modalities) including a total of 3012 patients met the inclusion criteria and were incorporated into this analysis. The estimated average probability of experiencing a major cardiac adverse event after treatment for in-stent restenosis with a follow-up period of 9±4 months was 30.0% (25.034.9%, 95% confidence interval) with strong evidence for heterogeneity between study specific results
. The clinical outcome was not significantly different between treatment modalities. After adjustment for confounding factors (i.e. lesion length), however, patients undergoing intracoronary radiation showed an estimated advantage of 16.9% (37.7±4.0%, 95% confidence interval) in MACE free survival, as compared to balloon angioplasty. The post-interventional diameter stenosis was the only independent predictor for the long-term outcome after treatment of in-stent restenosis.
Conclusions Treatment of in-stent restenosis is associated with an overall 30% rate of major adverse cardiac events. Currently, repeat angioplasty is the treatment option of choice, especially when a sufficient acute procedural result can be achieved. Intracoronary radiation should be considered in cases with therapy refractory forms of diffuse in-stent restenosis.
Key Words: Stent Restenosis Treatment Outcome Review Meta-analysis
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- A meta-analytical approach for the treatment of in-stent restenosis
- N Mercado and P.W Serruys
EHJ 2003 24: 217-218.[Extract] [FREE Full Text]
This article has been cited by other articles:
![]() |
D. J. Fiorella, E. I. Levy, A. S. Turk, F. C. Albuquerque, G. L. Pride Jr, H. H. Woo, B. G. Welch, D. B. Niemann, P. D. Purdy, B. Aagaard-Kienitz, et al. Target Lesion Revascularization After Wingspan: Assessment of Safety and Durability Stroke, January 1, 2009; 40(1): 106 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dibra, A. Kastrati, F. Alfonso, M. Seyfarth, M.-J. Perez-Vizcayno, J. Mehilli, and A. Schomig Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis: Meta-Analysis of Randomized Trials J. Am. Coll. Cardiol., February 6, 2007; 49(5): 616 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mukherjee and D. J. Moliterno Brachytherapy for In-Stent Restenosis: A Distant Second Choice to Drug-Eluting Stent Placement JAMA, March 15, 2006; 295(11): 1307 - 1309. [Full Text] [PDF] |
||||
![]() |
R Marcucci, D Brogi, F Sofi, C Giglioli, S Valente, A Alessandrello Liotta, M Lenti, A M Gori, D Prisco, R Abbate, et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting Heart, March 1, 2006; 92(3): 377 - 381. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Alfonso, J. M. Auge, J. Zueco, A. Bethencourt, J. R. Lopez-Minguez, J. M. Hernandez, J. A. Bullones, I. Calvo, E. Esplugas, M. J. Perez-Vizcayno, et al. Long-Term Results (Three to Five Years) of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Stenting (RIBS) Randomized Study J. Am. Coll. Cardiol., September 6, 2005; 46(5): 756 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-J. Neumann, W. Desmet, E. Grube, J. Brachmann, P. Presbitero, P. Rubartelli, A. Mugge, F. Di Pede, D. Fullgraf, W. Aengevaeren, et al. Effectiveness and Safety of Sirolimus-Eluting Stents in the Treatment of Restenosis After Coronary Stent Placement Circulation, April 26, 2005; 111(16): 2107 - 2111. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kastrati, J. Mehilli, N. von Beckerath, A. Dibra, J. Hausleiter, J. Pache, H. Schuhlen, C. Schmitt, J. Dirschinger, A. Schomig, et al. Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial JAMA, January 12, 2005; 293(2): 165 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W Radke, S. Kobella, A. Kaiser, A. Franke, D. Schubert, E. Grube, P. Hanrath, and R. Hoffmann Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary {beta}-radiation therapy Eur. Heart J., June 1, 2004; 25(11): 920 - 925. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Eto, S. Biro, M. Miyata, H. Kaieda, H. Obata, T. Kihara, K. Orihara, and C. Tei Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury Cardiovasc Res, July 1, 2003; 59(1): 200 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Mercado and P.W Serruys A meta-analytical approach for the treatment of in-stent restenosis Eur. Heart J., February 1, 2003; 24(3): 217 - 218. [Full Text] [PDF] |
||||






